Tests etentamig and ABBV-2001 in adults with multiple myeloma
Tests new antibody drugs, alone or with other drugs, in adults with multiple myeloma.
Plain-language title generated from the registry record
Registry title: A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Key facts
- Where
- Atlanta, Chapel Hill, Charlotte, Cincinnati, Columbus, Dallas, Denver, Duarte, Irvine, New York, Salt Lake City, San Francisco, Tampa, and Winston-Salem, United StatesSee the 15 sites
- Phase
- Phase 1/2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Source: NCT06892522, who can take part
Where in United States
- Winship Cancer Institute of Emory University /ID# 274830Atlanta, United StatesTaking people
- University of North Carolina at Chapel Hill /ID# 274667Chapel Hill, United StatesTaking people
- Atrium Health Levine Cancer Institute /ID# 276193Charlotte, United StatesTaking people
- Oncology Hematology Care - Blue Ash /ID# 272918Cincinnati, United StatesTaking people
- The Ohio State University /ID# 271336Columbus, United StatesTaking people
- University of Texas - Southwestern Medical Center /ID# 274360Dallas, United StatesTaking people
- Colorado Blood Cancer Institute /ID# 273129Denver, United StatesTaking people
- City of Hope National Medical Center /ID# 273132Duarte, United StatesTaking people
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277911Irvine, United StatesTaking people
- Mount Sinai - The Tisch Cancer Institute /ID# 272470New York, United StatesTaking people
- Weill Cornell Medical College /ID# 272517New York, United StatesTaking people
- Huntsman Cancer Institute /ID# 272575Salt Lake City, United StatesTaking people
- University Of California, San Francisco /ID# 271662San Francisco, United StatesTaking people
- Moffitt Cancer Center /ID# 272628Tampa, United StatesTaking people
- Atrium Health Wake Forest Baptist Medical Center /ID# 274847Winston-Salem, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbbVie
- Trial code
- NCT06892522EU 2024-515770-27-00
- Record updated
- 19 October 2026
- Original description
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig and ABBV-2001 in adult participants with MM.Read full original descriptionShow less
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig and ABBV-2001 in adult participants with MM.
Etentamig and ABBV-2001 are investigational drugs being developed for the treatment of MM. This study is broken into 8 substudies and each substudy consists of a dose escalation phase and dose expansion phase. Participants in substudies 1-4 will receive escalating doses of etentamig alone or with daratumumab and lenalidomide (DR), carfilzomib and dexamethasone (Kd) or lenalidomide (R), followed by etentamig at the dose levels established during the escalation phases alone or with DR, Kd and R. Participants in substudies 5-8 will receive up to two doses of ABBV-2001 or at the dose level(s) established during the escalation phases of ABBV-2001 with iberdomide, mezigdomide, pomalidomide or lenalidomide. Around 602 adult participants with MM will be enrolled at approximately 55 sites worldwide
In substudies 1-3, participants will receive escalating doses of etentamig as Intravenous (IV) infusions, alone or with DR, R or Kd, followed by SC injections of etentamig at the dose levels established during the escalation phases alone or with DR or K. In substudy 4, participants will receive escalating doses of etentamig as Intravenous (IV) infusions followed by SC injections of etentamig at the dose levels established during the escalation phase with Lenalidomide. In substudies 5-8, participants will receive up to two doses of ABBV-2001 as subcutaneous (SC) injections, with oral iberdomide, mezigdomide, pomalidomide or lenalidomide followed by SC injections of ABBV-2001 at the dose level(s) established during the escalation phases with oral iberdomide, mezigdomide, pomalidomide or lenalidomide. The study duration is approximately 130 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.
Inclusion: Eastern cooperative oncology group (ECOG) performance of <= 1; Confirmed diagnosis of multiple myeloma (MM) according to the International Myeloma Working Group (IMWG) diagnostic criteria with either newly diagnosed or relapsed or refractory (RR) MM, depending on the substudy.
Exclusion: Participant who has known active infection as outlined in the protocol; Participant who has known active central nervous system involvement of MM.